Send to

Choose Destination
Blood. 2018 Nov 1;132(18):1889-1898. doi: 10.1182/blood-2018-03-785972. Epub 2018 Sep 12.

How I treat breast implant-associated anaplastic large cell lymphoma.

Author information

Division of Oncology, Department of Medicine, Washington University in St. Louis, St. Louis, MO.
Department of Plastic Surgery, MD Anderson Cancer Center, Houston, TX; and.
Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY.


Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is a recently described form of T-cell non-Hodgkin lymphoma now formally recognized by the World Health Organization classification of lymphoid neoplasms. The disease most often presents with a delayed seroma around the breast implant, almost exclusively with a textured surface, and manifests with breast pain, swelling or asymmetry, capsular contracture, but can also present with a breast mass, and lymph node involvement. The prognosis of BIA-ALCL is favorable compared with many other subtypes of systemic T-cell lymphoma; however, unlike other non-Hodgkin lymphomas, complete surgical excision for localized disease is an important part of the management of these patients. In this paper, we share our recommendations for a multidisciplinary team approach to the diagnosis, workup, and treatment of BIA-ALCL in line with consensus guidelines by the National Comprehensive Cancer Network.

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center